VEGFA upregulation leads to growth of new blood vessels. Novel microRNA (miR-XXX) upregulates VEGFA gene. These RNAs are very effective in the treatment of myocardial infarction in animals. Discovered approach is completely new, yet undescribed biology of RNAs. Engineered exosomes as RNA carrier for targeting hypoxic tissues.
· Examination of FTO performed
· Patent application has been filed
The company is focusing on creating a treatment for two indications: Heart Failure and Peripheral Artery Disease.
Heart Failure. The aging population drives the heart failure market. The incidence, prevalence and therapeutics costs are increasing in the future. Currently available treatments are not effective enough for the growing healthcare problem. Heart failure drug market is expected to reach $11.8 Billion by 2025 (13.7% CAGR). Societal demand is very high since medical spending in the USA alone is more than $40 billion today. Efficient treatment for heart disease opens up the multi-billion market potential for the company able to bring such treatment to the market.
Peripheral Artery Disease. Global Peripheral Artery Disease Market was valued at $3,136 million in 2016 and is estimated to reach $4,980 million by 2023, growing at a CAGR of 6.8% from 2017 to 2023. Peripheral artery disease is a circulatory disease in which plaque builds up in the arteries carrying blood from the heart of the patient to legs and arms. An increase in the incidence of the population suffering from diabetes and high blood pressure, which poses a high-risk factor for peripheral artery disease, drives the market growth. Also, favorable reimbursement scenario for peripheral artery disease treatment and introduction of advanced treatments boost the market growth.